In a report released today, Alex Kramm from UBS maintained a Hold rating on CME Group, with a price target of $280.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alex Kramm’s rating is based on a combination of factors that suggest a cautious approach to CME Group’s stock. Despite an increase in the estimated earnings per share for the fourth quarter of 2025, driven by an 8% rise in total futures volume, Kramm remains hesitant to predict significant short-term gains. The potential benefits from macroeconomic uncertainty and new retail initiatives are acknowledged, but they are not deemed sufficient to alter the current outlook significantly.
Moreover, while November saw a notable increase in total average daily volume, particularly in equity index and metals complexes, other areas such as IRS clearing and EBS spot FX volume showed declines. The overall revenue per contract remained flat, with some areas experiencing a decrease. Given these mixed signals, Kramm maintains a neutral stance with a price target of $280, reflecting a balanced view of potential risks and opportunities.
According to TipRanks, Kramm is a 5-star analyst with an average return of 10.5% and a 59.49% success rate. Kramm covers the Financial sector, focusing on stocks such as CME Group, Intercontinental Exchange, and Marketaxess Holdings.
In another report released on December 3, Barclays also maintained a Hold rating on the stock with a $280.00 price target.